Neulumex

Barium Sulfate


E-z-em Canada Inc
Human Prescription Drug
NDC 32909-927
Neulumex also known as Barium Sulfate is a human prescription drug labeled by 'E-z-em Canada Inc'. National Drug Code (NDC) number for Neulumex is 32909-927. This drug is available in dosage form of Suspension. The names of the active, medicinal ingredients in Neulumex drug includes Barium Sulfate - 1 mg/mL . The currest status of Neulumex drug is Active.

Drug Information:

Drug NDC: 32909-927
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Neulumex
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Barium Sulfate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: E-z-em Canada Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Suspension
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:BARIUM SULFATE - 1 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Jun, 2021
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 22 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:E-Z-EM Canada Inc
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000180185
N0000010258
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:25BB7EKE2E
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class MOA:X-Ray Contrast Activity [MoA]
Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`.
Pharmacologic Class EPC:Radiographic Contrast Agent [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class:Radiographic Contrast Agent [EPC]
X-Ray Contrast Activity [MoA]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
32909-927-03450 mL in 1 BOTTLE, PLASTIC (32909-927-03)01 Jun, 2021N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Neulumex barium sulfate barium sulfate barium sulfate anhydrous citric acid benzoic acid dimethicone 350 dimethicone 1000 potassium sorbate saccharin sodium silicon dioxide sodium benzoate sorbitol trisodium citrate dihydrate water xanthan gum neulumex barium sulfate barium sulfate barium sulfate anhydrous citric acid benzoic acid dimethicone 350 dimethicone 1000 potassium sorbate saccharin sodium silicon dioxide sodium benzoate sorbitol trisodium citrate dihydrate water xanthan gum

Drug Interactions:

Drug interactions: the presence of barium sulfate formulations in the gi tract may alter the absorption of therapeutic agents taken concomitantly. in order to minimize any potential change in absorption, the separate administration of barium sulfate from that of other agents should be considered.

Indications and Usage:

Indications and usage: for use in computed tomography to opacify the gi tract.

Warnings:

Warnings: rarely, severe allergic reactions of an anaphylactoid nature, have been reported following administration of barium sulfate contrast agents. appropriately trained personnel and facilities should be available for emergency treatment of severe reactions and should remain available for at least 30 to 60 minutes following administration, since delayed reactions can occur.

General Precautions:

General: diagnostic procedures which involve the use of radiopaque contrast agents should be carried out under the direction of personnel with the requisite training and with a thorough knowledge of the particular procedure to be performed. a history of bronchial asthma, atopy, as evidenced by hay fever and eczema, or a previous reaction to a contrast agent, warrant special attention. caution should be exercised with the use of radiopaque media in severely debilitated patients and in those with marked hypertension or advanced cardiac disease. ingestion of barium is not recommended in patients with a history of food aspiration. if barium studies are required in these patients or in patients in whom integrity of the swallowing mechanism is unknown, proceed with caution. if barium is aspirated into the larynx, further administration should be immediately discontinued. information for patients: before administration of this product, patients receiving barium sulfate diagnostic agents shoul
d be instructed to: inform their physician if they are pregnant. inform their physician if they are allergic to any drugs or food, or if they have had any prior reactions to barium sulfate products or other contrast agents used in x-ray procedures (see precautions-general ). inform their physician about any other medications they are currently taking. seek immediate medical attention if they experience an allergic reaction after using this product. drug interactions: the presence of barium sulfate formulations in the gi tract may alter the absorption of therapeutic agents taken concomitantly. in order to minimize any potential change in absorption, the separate administration of barium sulfate from that of other agents should be considered.

Dosage and Administration:

Dosage and administration: the volume of the ct barium sulfate suspension to be administered will depend on the degree and extent of contrast required in the area(s) under examination and on the technique employed. for oral administration: gi tract marking: the patient should begin drinking neulumex approximately 20 – 30 minutes prior to the scheduled procedure. it is recommended that the patient consume multiple bottles, about 900 ml to 1,350 ml total volume prior to the exam or use as directed by physician. for improved gastric marking have patient consume the final 200 ml immediately prior to scan. bowel marking is consistent due to the uniformity of the 0.1% concentration of baso 4 . bowel lumen marking can be improved by increasing the volume of neulumex consumed (see below). other dosing regimens may be followed as applicable. in patients where marking is problematic, such as obesity and delayed transit, improved marking may be possible by increasing the total volume of neul
umex administered up to 1,800 ml or four (4) bottles.

Contraindications:

Contraindications: this product should not be used in patients with known or suspected gastrointestinal perforation or hypersensitivity to barium sulfate or any component of this barium sulfate formulation.

Adverse Reactions:

Adverse reactions: adverse reactions, such as nausea, vomiting, diarrhea and abdominal cramping, accompanying the use of barium sulfate formulations are infrequent and usually mild. severe reactions (approximately 1 in 1,000,000) and fatalities (approximately 1 in 10,000,000) have occurred. procedural complications are rare, but may include aspiration pneumonitis, granuloma formation, intravasation, embolization and peritonitis following intestinal perforation, vasovagal and syncopal episodes, and fatalities.

Drug Interactions:

Drug interactions: the presence of barium sulfate formulations in the gi tract may alter the absorption of therapeutic agents taken concomitantly. in order to minimize any potential change in absorption, the separate administration of barium sulfate from that of other agents should be considered.

Use in Pregnancy:

Usage in pregnancy: radiation is known to cause harm to the unborn fetus exposed in utero. therefore, radiographic procedures should only be used when, in the judgement of the physician, its use is deemed essential to the welfare of the pregnant patient.

Overdosage:

Overdosage: on rare occasions following repeated administration, severe stomach cramps, nausea, vomiting, diarrhea or constipation may occur. these indicated responses can be present in both fluoroscopic and ct procedures. these are transitory in nature and are not considered serious. symptoms may be treated according to currently accepted standards of medical care.

Description:

Description: neulumex is a barium sulfate suspension 0.1% w/v, 0.1% w/w for oral administration. each 100 ml contains 0.1 g barium sulfate. barium sulfate, due to its high molecular density is opaque to x-rays and therefore, acts as a positive contrast agent for radiographic studies. the active ingredient is barium sulfate and its structural formula is baso 4 . barium sulfate occurs as a fine, white, odorless, tasteless, bulky powder which is free from grittiness. its aqueous suspensions are neutral to litmus. it is practically insoluble in water, solutions of acids and alkalies, and organic solvents. inactive ingredients: citric acid, natural gum, benzoic acid, sodium citrate, natural and artificial blueberry flavor, potassium sorbate, purified water, saccharin sodium, simethicone emulsion, sodium benzoate, and sorbitol.

Clinical Pharmacology:

Clinical pharmacology: barium sulfate, due to its high molecular density is opaque to x-rays and, therefore, acts as a positive contrast agent for radiographic studies. barium sulfate is biologically inert and, therefore, is not absorbed or metabolized by the body, and is eliminated from the gi tract unchanged.

How Supplied:

How supplied: neulumex is supplied in the following quantity: 450 ml bottles, ndc 32909-927-03 rx only shake well prior to use manufactured by e-z-em canada inc for bracco diagnostics inc. monroe township, nj 08831 tel: 1-516-333-8230 1-800-544-4624 rev. 02/20 cl110501

Information for Patients:

Information for patients: before administration of this product, patients receiving barium sulfate diagnostic agents should be instructed to: inform their physician if they are pregnant. inform their physician if they are allergic to any drugs or food, or if they have had any prior reactions to barium sulfate products or other contrast agents used in x-ray procedures (see precautions-general ). inform their physician about any other medications they are currently taking. seek immediate medical attention if they experience an allergic reaction after using this product.

Package Label Principal Display Panel:

Neulumex carton ndc 32909-927-03 neulumex 32909-927-03 carton

Neulumex bottle ndc 32909-927-03 neulumex 32909-927-03 bottle


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.